Suppression of the renin-angiotensin-aldosterone axis with erythropoietin therapy by a negative feedback loop.
To investigate the pathophysiology of hypertension in patients receiving recombinant human erythropoietin (rHuEpo) we studied its effects on the renin-aldosterone axis of chronic haemodialysis (HD) patients not receiving antihypertensive drugs. Nine severely anaemic normotensive HD patients received rHuEpo 50 U/kg bodyweight, thrice weekly after each HD. The dose was increased by 25 U/kg bodyweight every 4 weeks to a maximum of 100 U/kg or until an increase of Hb or Hct of 2 g/dl or 7% was achieved. Blood samples were taken after 30 min supine rest and while seated 10 min later after gentle ambulation. Results expressed as mean +/- SEM: therapy in normotensive HD patients by a negative feedback loop, before the development of hypertension.
Yaqoob
M
M
Department of Renal Medicine, Royal Liverpool Hospital, UK.
Morris
K
K
Bell
G M
GM
Ahmad
R
R
D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000097:blood; D000740:Anemia / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D004921:Erythropoietin / Q000009:adverse effects*; D005246:Feedback; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000209:etiology; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects; D012083:Renin / Q000097:blood; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology
D006454:Hemoglobins; D004921:Erythropoietin; D000450:Aldosterone; D012083:Renin